-
Mashup Score: 5
In patients with heart failure with mildly reduced or preserved ejection fraction, oral dapagliflozin improved heart failure outcomes to a similar extent in three glycaemia subgroups: normoglycaemia, prediabetes, and type 2 diabetes. Moreover, the heart failure benefits of dapagliflozin seem to be consistent across a continuous glycaemic range.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status - 2 year(s) ago
Dysglycaemia is a metabolic state characterised by an HbA1c level above the normal range and includes anyone with slightly elevated glucose concentrations, impaired fasting glucose, impaired glucose tolerance, or diabetes. Since the term was first coined in 1996,1 analyses of many prospective studies have clearly shown a progressive relationship between the degree of dysglycaemia and…
Categories: Endocrinology, Latest HeadlinesTweet-
Hertzel C Gerstein & Naveed Sattar comment on: Reduction in heart failure outcomes with #SGLT2 inhibitors irrespective of #glycaemic status https://t.co/Bq1ZsB8yT8 #HeartFailure #diabetes
-
-
Mashup Score: 2
The past decade has seen substantial advances in the development of automated insulin delivery (AID) systems, which can improve glycaemic outcomes and burden of treatment for people with diabetes.1,2 AID systems use algorithms to adjust insulin delivery based in part on continuous glucose monitoring data. The first broadly available AID algorithm, OpenAPS, is open-source and was designed and…
Categories: Endocrinology, Latest HeadlinesTweet-
The past decade has seen substantial advances in the development of automated #insulin delivery (AID) systems, which can improve #glycaemic outcomes and burden of treatment for people with #diabetes https://t.co/yGXOz4Biyv #T1D #opensource #DIYAPS
-
-
Mashup Score: 0Glycaemic management in diabetes: old and new approaches - 2 year(s) ago
HbA1c is the most used parameter to assess glycaemic control. However, evidence suggests that the concept of hyperglycaemia has profoundly changed and that different facets of hyperglycaemia must be considered. A modern approach to glycaemic control should focus not only on reaching and maintaining optimal HbA1c concentrations as early as possible, but to also do so by reducing postprandial…
Categories: Endocrinology, Latest HeadlinesTweet-
#Glycaemic management in #diabetes: old and new approaches https://t.co/fuONBpPm9F #T1D #T2D https://t.co/WqVYOHChV5
-
-
Mashup Score: 1Glycaemic management in diabetes: old and new approaches - 2 year(s) ago
HbA1c is the most used parameter to assess glycaemic control. However, evidence suggests that the concept of hyperglycaemia has profoundly changed and that different facets of hyperglycaemia must be considered. A modern approach to glycaemic control should focus not only on reaching and maintaining optimal HbA1c concentrations as early as possible, but to also do so by reducing postprandial…
Categories: Endocrinology, Latest HeadlinesTweet-
#Glycaemic management in #diabetes: old and new approaches https://t.co/fuONBpPm9F #T1D #T2D https://t.co/oHW7QS6PhA
-
-
Mashup Score: 0Glycaemic management in diabetes: old and new approaches - 2 year(s) ago
HbA1c is the most used parameter to assess glycaemic control. However, evidence suggests that the concept of hyperglycaemia has profoundly changed and that different facets of hyperglycaemia must be considered. A modern approach to glycaemic control should focus not only on reaching and maintaining optimal HbA1c concentrations as early as possible, but to also do so by reducing postprandial…
Categories: Endocrinology, Latest HeadlinesTweet-
#Glycaemic management in #diabetes: old and new approaches https://t.co/fuONBpPm9F #T1D #T2D https://t.co/luRuUyMeYB
-
-
Mashup Score: 0Blood glucose targets in the critically ill: is one size fits all still appropriate? - 2 year(s) ago
In 2001, the paradigm for blood glucose control in hospitalised patients was challenged by a single-centre, randomised controlled trial (RCT).1 Conducted in mechanically ventilated surgical intensive care unit (ICU) patients (970 [63%] of 1548 following cardiovascular surgery and 1344 [87%] without a previous diagnosis of diabetes), this trial used intravenous insulin to target euglycaemia (blood…
Categories: Endocrinology, Latest HeadlinesTweet-
In the August Issue: Blood #glucose targets in the critically ill: is one size fits all still appropriate? https://t.co/O7L9GSshnA #ICU #glycaemic #management
-
-
Mashup Score: 2The Lancet Diabetes & Endocrinology, August 2022, Volume 10, Issue 8, Pages 549-608, e8 - 2 year(s) ago
Explore the current issue of The Lancet Diabetes & Endocrinology, a monthly journal focussed on diabetes, endocrinology, and metabolism
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet-
The August Issue of @TheLancetEndo is now online, featuring #brain #tumours, #radiotherapy, #COVID19, #vaccines, #diabetes, #BMI, #obesity, #T1D, #autoantibodies, #screening, #Genetics, #NCDs, #JunkFood ads, #insulin, #glycaemic management & more https://t.co/ft8CFDeSQz https://t.co/Q22sbeJ698
-
-
Mashup Score: 2
Once-weekly treatment with tirzepatide showed superior glycaemic control measured using CGM compared with insulin degludec in participants with type 2 diabetes on metformin, with or without a SGLT2 inhibitor. These new data provide additional evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal insulin.
Categories: Endocrinology, Latest HeadlinesTweet-
In the June Issue: Efficacy of once-weekly #tirzepatide versus once-daily insulin degludec on #glycaemic control measured by continuous glucose monitoring in adults with type 2 #diabetes (SURPASS-3 CGM): a substudy of the phase 3 SURPASS-3 trial https://t.co/qlpBxoBPhU #T2D #CGM
-
-
Mashup Score: 0SURPASSing the current dogma: is our framework shifting? - 2 year(s) ago
In their article in The Lancet Diabetes and Endocrinology, Tadej Battelino and colleagues1 report on a dedicated substudy of the parent SURPASS-3 randomised clinical trial, in which all three groups given the dual GLP-1 and GIP, tirzepatide (5 mg, 10 mg, or 15 mg weekly doses), had significantly greater reductions in HbA1c (estimated treatment difference [ETD] –0·59% to –1·04%, p<0·0001) and...
Categories: Endocrinology, Latest HeadlinesTweet-
Natasha P Malkani & Vanita R Aroda comment on: SURPASSing the current dogma: is our framework shifting? https://t.co/6I1GtjqH5B #tirzepatide #glycaemic control #CGM
-
New—Efficacy and safety of #dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline #glycaemic status (#DELIVER): a subgroup analysis from a multicentre, double-blind, randomised, placebo-controlled trial https://t.co/YDLCsqAw1s